Loading…
← CockpitCompetitor Analysis › 300639.SZ Guangdong Hybribio Biotech Co Ltd Class AOpen in the cockpit ↗

Guangdong Hybribio Biotech Co Ltd Class A300639.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum neutral 48
Mkt cap
$511M
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$13.1M
20-day average traded
Fwd P/E
57.3×
forward earnings
ROIC−WACC
-1.3 pp
WACC 5.6%
Hurdle
+14 pp
Req g minus delivered
Next earnings
142 days
9 Apr 2027
Close · CNYCN¥5.18
1D-1.3%
1W-9.1%
1M-17.2%
3M-17.4%
6M-17.9%
YTD-3.7%
1Y-12.9%
ATR %4.5%
52w lowhigh48.6% off high

What Guangdong Hybribio Biotech does

Employees: 1,990

Guangdong Hybribio Biotech at a glance

Size Guangdong Hybribio Biotech (300639.SZ) is a China Health Care company (Medical Specialties) with a market value of $511M, the 3650th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥5.18 on 18 Nov 2026.

Performance Over six months the shares fell 17.9%, against -17.4% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue fell 7.2% over the last twelve months (peer median +7.0%); the operating margin is 4.4% (peer median 2.2%).

Valuation It trades at 57.3× forward earnings against a peer median of 21.1× (most expensive of 9).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is -13%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.3 points below its cost of capital (5.6% WACC).

Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 85300639.SZ 82
Six months, rebased to 100: Guangdong Hybribio Biotech against the median of its 20 peers (local-currency closes).

Guangdong Hybribio Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥642MCN¥665MCN¥812MCN¥1.10BCN¥5.58B
Revenue growth—-18%-26%-80%—
Gross profitCN¥353MCN¥215MCN¥296MCN¥579MCN¥3.76B
EBITDAn/a-CN¥16.2M-CN¥615MCN¥189MCN¥2.61B
Net incomeCN¥66.7M-CN¥131M-CN¥655MCN¥140MCN¥1.73B
Free cash flowCN¥231MCN¥251M-CN¥69.6M-CN¥58.1MCN¥575M
Capital expenditureCN¥147MCN¥92.4MCN¥148MCN¥385MCN¥734M
Total debtCN¥178MCN¥89.6MCN¥87.5MCN¥56.7MCN¥139M

Quarterly statements and history in the cockpit →

Guangdong Hybribio Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%7979AVR688075NNNN300439688298688580MEDXRCELMYGNZJYL603520002932605369300869CEVIANGO300639.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Guangdong Hybribio Biotech is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×60×7979688580MEDX603520688606301033605369CEVI300639.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Guangdong Hybribio Biotech is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%688075300439688580MEDX688606301033605369300246300869CEVI300639.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Guangdong Hybribio Biotech is the large dot.

Guangdong Hybribio Biotech competitors and peer comparison

How Guangdong Hybribio Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Guangdong Hybribio Biotech against its 20 peers (data as of 18 Nov 2026)
Measure300639.SZPeer medianRank in peer set
1-month return-17.2%-4.6%lowest of 21
6-month return-17.9%-17.4%11th highest of 21
Distance from 52-week high-48.6%-40.8%5th lowest of 21
Revenue growth (TTM)-7.2%+7.0%4th lowest of 21
Operating margin4.4%2.2%9th highest of 21
Forward P/E57.3×21.1×most expensive of 9
Growth the price implies (Req g, 7 yrs)0.4%8.7%2nd least demanding of 11
Growth delivered (Del g)-13.2%-0.1%3rd lowest of 11
Hurdle (Req g minus delivered)+13.6 pp+8.8 pp6th least demanding of 11
ROIC minus cost of capital-1.3 pp-2.2 pp8th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%57.3×0.4%-13.2%
Shofu 7979.TJapan$510M+32%+9%14%13.2×n/an/a
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%n/an/an/a
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%n/a30.8%-18.6%
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%n/a6.0%-7.7%
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%n/an/an/a
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%19.7×20.1%+4.2%
medmix MEDX.SWSwitzerland$494M+11%-7%6%19.4×4.5%+5.0%
AVITA Medical RCELUnited States$529M+290%+17%-34%n/an/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%n/an/an/a
Jin Medical International ZJYLUnited States$532M+47%-14%2%n/an/an/a
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%25.8×n/an/a
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%6.9×-6.5%-4.3%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%31%22.4×4.3%+24.4%
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%23.5×10.2%+6.5%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-8%n/a55.3%-4.7%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%n/a15.0%-19.8%
CellaVision CEVI.STSweden$477M+64%+2%23%32.6×7.1%+10.0%
AngioDynamics ANGOUnited States$476M-4%+8%-6%n/an/an/a

Questions

Which companies are Guangdong Hybribio Biotech's closest peers?
The cockpit's peer set: Shofu (7979.T), Anteris Technologies Global (AVR), Assure Tech (Hangzhou) (688075.SS), Anbio Biotechnology (NNNN), MedicalSystem Biotechnology (300439.SZ), Zhejiang Orient Gene Biotech (688298.SS), Nanjing Vishee Medical Technology (688580.SS), medmix (MEDX.SW).
Is Guangdong Hybribio Biotech expensive compared with its peers?
On forward p/e it trades at 57.3× against a peer median of 21.1×, most expensive of 9 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is -13%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Guangdong Hybribio Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -17.9% against -17.4% for the median peer; over one year -12.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.